StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Eli Lilly & Co. (LLY) Announces Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio (Abemaciclib)
October 10, 2017 6:46 AM
Eli Lilly and Company (NYSE: LLY) today announced that its Phase 3 JUNIPER study evaluating Verzenio™ (abemaciclib), a cyclin-dependent kinase ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Hot Corp. News
Hot FDA News
Management Comments
Next Articles
Eli Lilly (LLY) PT Raised to $73 at BMO Capital on 3Q Preview; 'In-Line to Incrementally Positive Quarter'
October 10, 2017 9:42 AM
Lilly Reports Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio™ (abemaciclib) in KRAS-Mutated, Advanced Non-Small Cell Lung Cancer
October 10, 2017 6:45 AM
Credit Suisse Downgrades Eli Lilly (LLY) to Neutral
October 10, 2017 4:59 AM
Eli Lilly & Co. (LLY) Reports Interim Results for MONARCH 3 Study Highlighting Benefit of Verzenio (Abemaciclib) Plus NSAI in Advanced Breast Cancer
October 6, 2017 1:02 PM
